THE TRIPLE COMBINATION OF VENETOCLAX-IBRUTINIB-OBINUTUZUMAB PROLONGS PROGRESSION-FREE SURVIVAL COMPARED TO VENETOCLAX-CD20-ANTIBODY COMBINATIONS AND CHEMOIMMUNOTHERAPY IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: FINAL ANALYSIS FROM THE PHASE 3 GAIA/CLL13 TRIAL